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INTRODUCTION 
Diabetic nephropathy is a spectrum of progressive renal 
lesions secondary to diabetes mellitus ranging from renal 
hyper filtration to end stage kidney disease and 
responsible for significant morbidity and mortality 
among the Diabetic population1. It occurs as a 
microvascular complication of both insulin dependent 
(IDDM) and non-insulin dependent (NIDDM) diabetes 
mellitus characterised by persistent proteinuria, decline 
in glomerular filtration rate (GFR)2. The overall 
prevalence of diabetic nephropathy varies from 20 - 40% 
in diabetic patients2. It occurs in 30% of type I diabetics, 
5 to 15 years after diagnosis but may be present at 
diagnosis in type II diabetics, as the time of onset of type 
II diabetes is often unknown1. Diabetic nephropathy is 
also the most common cause of end stage renal disease 
(ESRD) and has a devastating impact on morbidity and 
mortality of patients with diabetes mellitus1. 
Known risk factors for the development of diabetic 
nephropathy include genetic predisposition, poor 
glycaemic control, hypertension and smoking1. 
Prevention, early detection and aggressive intervention 
are needed to retard the progression of diabetic 
nephropathy to end stage renal failure1,2.  
The earliest clinical evidence of nephropathy is the 
presence of microalbuminuria.. Microalbuminuria 
progresses to overt proteinuria over the next 7 to 10 
years. Once overt proteinuria develops, renal function 
progressively declines and end stage renal failure is 
reached after about 10 years1,2. Microalbuminuria is a 
powerful and independent predictor of cardiovascular 
death3. 
The management of diabetic nephropathy includes good 
glycaemic control, tight control of blood pressure and 
reduction of proteinuria with cessation of smoking, lipid 
control and salt and protein restriction4. Therapeutic 
intervention is intended to prevent or retard the 
progression of diabetic renal disease as well as to reduce 
cardiovascular complications4.  
Independent of their antihypertensive effect, reno 
protective agents like ACEIs5 (Angiotensin Converting 
Enzyme inhibitors) and ARBs6 (Angiotensin receptor 
blokers) have been shown to reduce microalbuminuria as 
well as overt proteinuria, associated with Diabetes. 
Landmark clinical trials of ACEIs in type I 7 and ARBs 
in type II 8 diabetics have clearly demonstrated the 
effectiveness of these agents to retard the progression of 
overt diabetic nephropathy. Therefore, ACEIs and ARBs 
should be instituted even in the settings of moderately 
severe renal failure9. 
Several small studies have indicated that the combination 
of ACEI and ARB may have additive effect in lowering 
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blood pressure and proteinuria in diabetic patients with 
microalbuminuria and overt nephropathy10.  
Drug utilization studies are conducted frequently all over 
the world. In developing countries with the constraint of 
health budget for drugs, it becomes even more 
meaningful to prescribe drugs rationally. These studies 
can thus help to set priorities for the rational allocation of 
health care budgets and can ascertain the role of drugs in 
society. The present study was undertaken in a tertiary 
care hospital to evaluate the current drug utilization 
pattern in patients with Diabetic nephropathy and to 
facilitate rational use of drugs in such patient population. 
 
MATERIALS AND METHODS 
The study began after the approval from the Institutional 
Ethics Committee. Data was collected from 313 case 
sheets of Diabetic patients, who got admitted in 
Nephrology department at Sri Ramachandra Hospital, 
Chennai, from June 2009 to December 2010 with 
proteinuria on urine analysis. Later, the detailed analysis 
of drug utilization pattern was performed statistically. 
However, we did not include pregnant and lactating 
mothers and the patients who are on hemodialysis 
support. 
Patients attending outdoors were not considered either. 
This study was a non interventional observation in 
nature. 
 
RESULTS: 
From the demographic details (Table 1), male sex 
appeared to be affected more than female with Diabetic 
nephropathy (63.2% versus 36.8%). A significant 
number of patients also had co morbidities like 
Hypertension (76.9%), Dyslipidemia (61.3%) and 
Obesity (39.3%). 
Table 1: Demographic details of all the patients 
Total patients 313 
Male 198 (63.2%) 
Female 115 (36.8%) 
Mean age (years) 37.6 ± 24.7 
Mean duration of disease (years) 12.6  ± 4.2 
Smokers 208 (66.5%) 
Type 1 DM cases 135 (43.1%) 
Type 2 DM cases 178 (56.9%) 
Associated Hypertension 241 (76.9%) 
Associated Dyslipidemia 192 (61.3%) 
Associated obesity 123 (39.3%) 
 
There was lesser number of patients of Type1 DM than 
Type 2 in our study. 
Table 2: Details of the drug utilization pattern 
Classes of Drugs with examples Percentage of 
patients received 
the drug* 
ACE inhibitor (Enalapril, Ramipril) 32% 
ARB (Losartan, Telmisartan, 
Olmesartan) 
68% 
CCB (Amlodipine, Cilnidipine) 48% 
Diuretics (Hydrocholorthiazide) 55% 
Statins (Atorvastatin, Rosuvastatin) 63% 
(Insulin and/or OHAs) 100% 
 *Rounded off to nearest whole number 
Insulin and or oral hypoglycemic agents were universally 
prescribed among all the patients as anti diabetic therapy 
(Table 2). Similarly, all of them received at least one 
drug that inhibits RAAS (Renin Angiotensin Aldosterone 
system) in the form of ACE inhibitors (32%) or ARBs 
(68%). Diuretics and CCBs were prescribed in 55% and 
48% respectively. 
 
Table 3: Dosage and frequency of administration of individual drugs 
Drug Most frequently prescribed dose Maximum prescribed dose 
Enalapril 5 mg BD 20mg BD 
Ramipril 2.5mg OD 10mg OD 
Losartan 50mg OD 50mg BD 
Telmisartan 40mg OD 80mg OD  
Olmesartan 20mg OD 40mg OD 
Hydrochlorothiazide 12.5mg OD 25mg OD 
Amlodipine 5mg OD 20 mg OD 
Cilnidipine 10mg OD 20mg OD 
Atorvastatin 10mg OD 40mg OD 
Glimepiride 2mg OD 6mg OD 
Glipizide 10mg OD 20mg OD 
OD: once daily, BD: twice daily 
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Table 4: Most frequently utilized agents from different drug classes 
Drug class Percentage of usage 
ACE inhibitors Ramipril (58%), Enalapril (42%) 
ARBs Losartan (44%), Telmisartan (39%), 
Olmesartan (17%) 
CCBs Amlodipine (84%), Cilnidipine (16%) 
Statins Atorvastatin(76%),Rosuvastatin (14%) 
Sulfonylurea Glimepiride (69%), Glipizide (31%) 
*Rounded off to nearest whole number 
Table 5: Fixed dose combination therapy used in Diabetic nephropathy 
Drug combination Examples 
ARB + Diuretics 
 
Losartan(50mg) + Hydrochlorothiazide(12.5mg) 
Telmisartan(40mg) + Hydrochlorothiazide(12.5mg)  
ARB + CCB 
 
Losartan(25/50mg) + Amlodipine (5mg) 
Telmisartan(40/80mg) + Amlodipine (5mg) 
Olmesartan (20/40mg) + Amlodipine (5mg) 
Telmisartan(40mg) + Cilnidipine (10mg) 
ARB + CCB + Diuretics 
 
Losartan(50mg)+Amlodipine(5mg)+Hydrochlorothiazide(12.5mg) 
Telmisartan(40mg)+Amlodipine(5mg)+Hydrochlorothiazide(12.5mg) 
Olmesartan(20mg)+Amlodipine(5mg)+Hydrochlorothiazide(12.5mg) 
ACE inhibitors + 
Diuretics 
Enalapril(5mg) + Hydrochlorothiazide(12.5mg) 
Ramipril(2.5/5mg) + Hydrochlorothiazide(12.5mg) 
Statin + Fibrate 
 
Atorvastatin (10mg) + Fenofibrate (160mg) 
Rosuvastatin (10mg) + Fenofibrate (160mg) 
 
Table 6: Physician’s Advice 
Physician’s advice Percentage 
Anti Diabetic diet 25% 
Protein restriction 85% 
Salt restriction 60% 
Avoid Nephrotoxic drugs 25% 
Physical exercise 30% 
 
DISCUSSION  
A changing life style in developing countries like India 
has enormously increased the statistical figures of 
chronic diseases like diabetes mellitus, hypertension and 
chronic kidney disease11. One of the most common 
causes of renal disorders associated with proteinuria in 
our tertiary care hospital is Diabetic nephropathy.  
Table 1 implies that 63.2 % of patients are males. The 
reason could be increased smoking habit found among 
men in India, which would have accelerated the 
progression of Diabetic and non-diabetic renal disease12. 
In fact 66.5% of patients here had a positive smoking 
history. Close association with Hypertension, 
Dyslipidemia and Obesity was also evident. 
Type II DM constituted more number of cases than type 
I here (56.9% vs. 43.1%). This is probably because of 
early diagnosis and initiation of therapy in the latter, 
where patients become symptomatic much before than 
type II. 
Since a tight glycemic control is the most important 
factor to halt the process of nephropathy, all patients 
were given anti diabetic therapy with either Oral 
hypoglycemic agents and or Insulin (Table2). Different 
forms of Insulin were prescribed on the basis of patient’s 
requirement, while Glimepiride appeared to be the most 
commonly used oral agent. 
Due to their established efficacy in Diabetic 
nephropathy, ACEIs (32%) and ARBs (68%) were the 
two most frequently utilized drugs in this setup5.6. In our 
study there was practically no patient, who did not get at 
least one drug from these two groups. 
In type I diabetic patients with or without hypertension, 
ACEIs have been shown to reduce microalbuminuria5, 
while  in type II diabetics, ACEIs and more recently 
ARBs have been shown to reduce microalbuminuria6. 
Clinical trials involving ACEIs and ARBs in Diabetic 
nephropathy have shown significant reductions in the 
risk of doubling of plasma creatinine and developing 
renal failure. These benefits were independent of blood 
pressure lowering7, 8. 
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There is also clinical evidence regarding the initiation of 
ACEIs or ARBs even in the settings of moderately 
severe renal failure. Although, the renal function should 
be carefully monitored in those patients9. 
According to a trial done by Brenner, Parving et al, 
ARBs are better than ACE inhibitors in reno-protection 
beyond blood pressure control8. ARB may produce reno-
protective benefits by lowering the fibrogenic cytokine 
Transforming Growth Factor-β (TGF β), reducing 
proteinuria, decreasing renal oxidative stress, preserving 
glomerular and tubulointerstitial structure and reducing 
the glomerular membrane pore size6,8.  
The choice between ACEIs and ARBs depends on the 
followings conditions; 13 
 In hypertensive Type I diabetic patients with any 
degree of albuminuria, ACE inhibitors have been 
shown to delay the progression of nephropathy. 
 In hypertensive Type II diabetic patients with 
microalbuminuria, ACE inhibitors and ARBs have 
shown to delay the progression. 
 In patients with Type II diabetes, hypertension, 
macroalbuminuria, and renal insufficiency (serum 
creatinine >1.5 mg/dl), ARBs have been shown to 
delay the progression of nephropathy.  
ACEIs and ARBs should be used with caution in patients 
with bilateral renal artery stenosis or renal artery stenosis 
of a single functioning kidney. ACEIs and ARBs should 
be started at lower doses in renal failure and titrated 
gradually to maximal tolerable dose to achieve anti-
proteinuric effect. Serum potassium and creatinine 
should be checked prior to and within one to two weeks 
after initiating an ACEI or ARB as they can occasionally 
cause worsening of renal function13. 
Diuretics potentiate the antihypertensive and anti-
proteinuric effect of ACEIs and    ARBs14. This explains 
why Hydrochlorothiazide was prescribed in 55% of our 
patients. 
We also found Calcium channel blockers (CCBs) like 
Amlodipine and Cilnidipine to be other commonly 
prescribed agents (table 2), as they have some class 
specific effect on proteinuria. However, the effect may 
be variable with different Dihydropyridines (e.g. 
nifedipine, amlodipine) 15. Recently, there are clinical 
evidences in favour of anti proteinuric effect of 
Cilnidipine16. In our study, it was the second commonest 
CCB used after Amlodipine (Table 4). 
Treatment of hyperlipidemia with lipid lowering drugs 
like Atorvastatin, smoking cessation, dietary protein 
restriction, salt restriction  also play a major role in 
halting the progression of diabetic nephropathy. Very 
recent study has proved the role of Atorvastatin in 
reduction of renal cholesterol synthesis in rat17. 
Table 5 demonstrates the combination drug therapy used 
in our tertiary care hospital for diabetic nephropathy. The 
multifactorial etiologies of the disease suggest that multi-
interventional approach is mandatory to halt the 
progression of renal disorders and for the reversal of 
renal microvascular complications. Drugs from two or 
more groups are often combined for this purpose. We 
observed that ARBs with Diuretics or CCBs are the most 
frequently utilized drug combination. 
Table 6 shows the physicians’ advice given to the patient 
with renal disorders associated with proteinuria. Majority 
of them were advised protein restricted diet and salt 
restriction. A study by Koya et al has shown that a low-
protein diet could prevent the progression of diabetic 
nephropathy18. 
CONCLUSION 
Early detection of renal disorders and the adoption of 
multifactorial interventions targeting the main risk 
factors (Hypertension, Hyperglycemia, Dyslipidemia, 
Smoking) and the use of reno-protective agents such as 
ARBs and or ACEIs, may delay the progression of renal 
disease besides reducing the cardiovascular morbidity 
and mortality.                                                          
From our study, it shows that the most commonly 
prescribed drugs in patients suffering from Diabetic 
nephropathy with proteinuria are ARBs and ACE 
inhibitors beside the anti diabetic therapy. Among those, 
ARBs are more frequently prescribed than ACE 
Inhibitors.  
Combination therapy of drugs was prescribed owing to 
the multifactorial etiology and pathogenesis of the 
disease. ARB with Diuretics or CCBs appeared to be the 
most commonly prescribed combination therapy. 
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